{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T20:39:15.396465+00:00","company":{"ticker":"NVAX","cik":1000694,"company_name":"NOVAVAX INC"},"pagination":{"limit":100,"returned":53,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Gavi Alliance","detail":"supply","count":3,"first_seen":"2022-11-21T23:59:59+00:00","last_seen":"2024-02-22T23:59:59+00:00","evidence_fact_ids":[72519,72520,194947]},{"display_name":"SK bioscience Co., Ltd.","detail":"settlement","count":3,"first_seen":"2023-08-08T23:59:59+00:00","last_seen":"2023-08-08T23:59:59+00:00","evidence_fact_ids":[121861,121862,121863]},{"display_name":"J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC","detail":"notes_offering","count":2,"first_seen":"2022-12-19T23:59:59+00:00","last_seen":"2022-12-28T23:59:59+00:00","evidence_fact_ids":[188729,190188]},{"display_name":"FUJIFILM Diosynth Biotechnologies UK Limited, FUJIFILM Diosynth Biotechnologies Texas, LLC, and FUJIFILM Diosynth Biotechnologies USA, Inc.","detail":"settlement","count":1,"first_seen":"2024-03-26T23:59:59+00:00","last_seen":"2024-03-26T23:59:59+00:00","evidence_fact_ids":[64875]},{"display_name":"His Majesty the King in right of Canada","detail":"supply","count":1,"first_seen":"2023-07-07T23:59:59+00:00","last_seen":"2023-07-07T23:59:59+00:00","evidence_fact_ids":[133010]},{"display_name":"Pfizer Inc.","detail":"license","count":1,"first_seen":"2026-01-20T23:59:59+00:00","last_seen":"2026-01-20T23:59:59+00:00","evidence_fact_ids":[35141]},{"display_name":"Sanofi Pasteur Inc.","detail":"collaboration","count":1,"first_seen":"2024-05-13T23:59:59+00:00","last_seen":"2024-05-13T23:59:59+00:00","evidence_fact_ids":[46794]},{"display_name":"The Bank of New York Mellon Trust Company, N.A.","detail":"notes_offering","count":1,"first_seen":"2022-12-21T23:59:59+00:00","last_seen":"2022-12-21T23:59:59+00:00","evidence_fact_ids":[189617]}],"lender":[{"display_name":"The Bank of New York Mellon Trust Company, N.A.","detail":"convertible_notes","count":2,"first_seen":"2022-12-21T23:59:59+00:00","last_seen":"2025-08-27T23:59:59+00:00","evidence_fact_ids":[42312,189620]},{"display_name":"J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC","detail":"convertible_notes","count":1,"first_seen":"2022-12-28T23:59:59+00:00","last_seen":"2022-12-28T23:59:59+00:00","evidence_fact_ids":[188731]}],"ma_counterparty":[{"display_name":"Novo Nordisk Production Czech s.r.o.","detail":"disposition","count":1,"first_seen":"2024-12-30T23:59:59+00:00","last_seen":"2024-12-30T23:59:59+00:00","evidence_fact_ids":[101877]}]},"facts":[{"fact_type":"earnings_release","fact_key":"e2d2a33482f37a1df9749ba72910fc01342ca38b","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2026-05-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ended March 31, 2026","report_date":"2026-05-06","result_type":"reported_results","revenue_text":"Total revenue of $140 million in the first quarter of 2026"},"claim":"NOVAVAX INC reported the first quarter ended March 31, 2026 results: revenue Total revenue of $140 million in the first quarter of 2026. Guidance reaffirmed.","evidence_excerpt":"Novavax Reports First Quarter 2026 Financial Results and Operational Highlights • Total revenue of $140 million in the first quarter of 2026","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-030924","anchor_url":"https://secwatch.observer/filing/0001628280-26-030924#claim-e2d2a33482f37a1df9749ba72910fc01342ca38b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000162828026030924/0001628280-26-030924-index.htm"},{"fact_type":"material_agreement","fact_key":"166a4da24dccc48a2bcff738fdd79434b931f801","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2026-01-20T23:59:59+00:00","payload":{"action":"entry","agreement_name":"License and Option Agreement","agreement_type":"license","counterparty":"Pfizer Inc.","effective_date":"2026-01-15","item_codes_triggered":["1.01"],"value_text":"$30 million"},"claim":"NOVAVAX INC entered into License and Option Agreement with Pfizer Inc. valued at $30 million (effective 2026-01-15).","evidence_excerpt":"On January 15, 2026, (the “Effective Date”), Novavax, Inc. (the “Company”) entered into a License and Option Agreement (the “License and Option Agreement”) with Pfizer Inc. (“Pfizer”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-004785","anchor_url":"https://secwatch.observer/filing/0001104659-26-004785#claim-166a4da24dccc48a2bcff738fdd79434b931f801","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465926004785/0001104659-26-004785-index.htm"},{"fact_type":"restructuring_charge","fact_key":"61e6fa134b399896b5d5adb5b333fcb8b9c1c6c2","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2025-10-22T23:59:59+00:00","payload":{"affected_area":null,"charge_text":"$29 million","effective_date":"2025-08-27","event_type":"impairment","headcount_text":null,"item_codes_triggered":["2.06"]},"claim":"NOVAVAX INC announced a impairment with charges of $29 million.","evidence_excerpt":"the Company expects to recognize a non-cash charge of $29 million during the third quarter of 2025 associated with the extinguishment of the 5.00% Convertible Senior Notes due 2027 and announced on August 27, 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-101390","anchor_url":"https://secwatch.observer/filing/0001104659-25-101390#claim-61e6fa134b399896b5d5adb5b333fcb8b9c1c6c2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925101390/0001104659-25-101390-index.htm"},{"fact_type":"restructuring_charge","fact_key":"5632e266cc68f3f8f58531c509363ebf7e908b40","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2025-10-22T23:59:59+00:00","payload":{"affected_area":"700 Quince Orchard Road, Gaithersburg, MD facility","charge_text":"between $96 million and $98 million","effective_date":"2025-10-17","event_type":"impairment","headcount_text":null,"item_codes_triggered":["2.06"]},"claim":"NOVAVAX INC announced a impairment with charges of between $96 million and $98 million affecting 700 Quince Orchard Road, Gaithersburg, MD facility.","evidence_excerpt":"on October 17, 2025, the Company concluded that it expects to recognize an estimated non-cash impairment charge of between $96 million and $98 million in the third quarter of 2025, which includes the write off of the right-of-use asset, property and equipment, and intangibles, partially offset by a gain recognized on the sale of adjacent land under the Parcel Agreement.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-101390","anchor_url":"https://secwatch.observer/filing/0001104659-25-101390#claim-5632e266cc68f3f8f58531c509363ebf7e908b40","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925101390/0001104659-25-101390-index.htm"},{"fact_type":"debt_financing","fact_key":"d1742707c40cdbd64040c8c198df1c7861c870b0","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2025-08-27T23:59:59+00:00","payload":{"counterparty":"The Bank of New York Mellon Trust Company, N.A.","effective_date":"2025-08-27","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"4.625% per annum","item_codes_triggered":["2.03"],"maturity_text":"September 1, 2031","principal_text":"$225.0 million aggregate principal amount"},"claim":"NOVAVAX INC incurred convertible notes of $225.0 million aggregate principal amount with The Bank of New York Mellon Trust Company, N.A. at 4.625% per annum maturing September 1, 2031.","evidence_excerpt":"On August 27, 2025, Novavax, Inc. (the “Company”) consummated (the “Closing”) the previously announced privately negotiated exchange and subscription transactions, pursuant to which it issued $225.0 million aggregate principal amount of its 4.625% Convertible Senior Notes due 2031 (the “Notes”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-084053","anchor_url":"https://secwatch.observer/filing/0001104659-25-084053#claim-d1742707c40cdbd64040c8c198df1c7861c870b0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925084053/0001104659-25-084053-index.htm"},{"fact_type":"executive_change","fact_key":"b772a63fca","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2025-05-27T23:59:59+00:00","payload":{"action":"terminated","action_category":"departure","departure_tone":"routine","effective_date":"2025-06-20","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"John Trizzino was terminated as Chief Operating Officer at NOVAVAX INC.","evidence_excerpt":"determined to eliminate the position of Chief Operating Officer, and terminate the employment of John Trizzino with the Company effective as of June 20, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-052959","anchor_url":"https://secwatch.observer/filing/0001104659-25-052959#claim-b772a63fca","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925052959/0001104659-25-052959-index.htm"},{"fact_type":"executive_change","fact_key":"694202f371","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2025-04-29T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-04-25","interim":false,"role":"Class III director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Charles W. Newton was appointed as Class III director at NOVAVAX INC.","evidence_excerpt":"appointed Charles W. Newton. to the Board, effective on such date, to fill the resulting vacancy and to serve as a Class III director","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-25-040656","anchor_url":"https://secwatch.observer/filing/0001104659-25-040656#claim-694202f371","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925040656/0001104659-25-040656-index.htm"},{"fact_type":"executive_change","fact_key":"4e579bb255","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2025-03-11T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-03-10","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"John W. Shiver was appointed as Director at NOVAVAX INC.","evidence_excerpt":"On March 10, 2025, the Board appointed John W. Shiver, Ph.D. to the Company’s Board, effective on such date, to fill the vacancy created by Dr. Young’s resignation and to serve as a Class III director for a term expiring at the Company’s 2025 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-022588","anchor_url":"https://secwatch.observer/filing/0001104659-25-022588#claim-4e579bb255","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925022588/0001104659-25-022588-index.htm"},{"fact_type":"executive_change","fact_key":"bbe731872c","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2025-03-11T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-03-10","interim":false,"role":"Chairperson of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Margaret G. McGlynn was appointed as Chairperson of the Board at NOVAVAX INC.","evidence_excerpt":"Margaret G. McGlynn was appointed to serve as the Chairperson of the Board to succeed Dr. Young.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-022588","anchor_url":"https://secwatch.observer/filing/0001104659-25-022588#claim-bbe731872c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925022588/0001104659-25-022588-index.htm"},{"fact_type":"executive_change","fact_key":"480e15a5c7","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2025-03-11T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-03-10","interim":false,"role":"Chairperson of the Board","role_category":"chair","successor_name":"Margaret G. McGlynn","successor_named":true},"claim":"James F. Young resigned as Chairperson of the Board at NOVAVAX INC.","evidence_excerpt":"On March 10, 2025, James F. Young, Ph.D. resigned from the Board of Directors (the “Board”) of Novavax, Inc. (the “Company”), effective as of March 10, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-022588","anchor_url":"https://secwatch.observer/filing/0001104659-25-022588#claim-480e15a5c7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465925022588/0001104659-25-022588-index.htm"},{"fact_type":"ma_transaction","fact_key":"69687a135550951a001d9c412d266896100f2785","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2024-12-30T23:59:59+00:00","payload":{"action":"disposition","closing_date":"2024-12-30","consideration_text":"$200 million and the assumption by the Purchaser of liabilities","counterparty":"Novo Nordisk Production Czech s.r.o.","effective_date":"2024-12-30","item_codes_triggered":["2.01"]},"claim":"NOVAVAX INC completed a disposition involving Novo Nordisk Production Czech s.r.o. for $200 million and the assumption by the Purchaser of liabilities (closed 2024-12-30).","evidence_excerpt":"(iii) certain employees currently providing services related to the Transferred Assets (the “Transferred Employees”).\nThe total purchase price for the Facility was $200 million and the assumption by the Purchaser of liabilities (on a look-forward basis)\npertaining to the Transferred Assets, Transferred Contracts and Transferred Employees. On the closing","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-132569","anchor_url":"https://secwatch.observer/filing/0001104659-24-132569#claim-69687a135550951a001d9c412d266896100f2785","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465924132569/0001104659-24-132569-index.htm"},{"fact_type":"executive_change","fact_key":"6b89d27d43","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2024-05-23T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":"2024-06-30","interim":false,"role":"President, Research and Development","role_category":"president","successor_name":null,"successor_named":false},"claim":"Filip Dubovsky retired as President, Research and Development at NOVAVAX INC.","evidence_excerpt":"On May 20, 2024, Filip Dubovsky notified Novavax, Inc. (the “Company”) of his decision to retire as President, Research and Development, effective as of June 30, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-064680","anchor_url":"https://secwatch.observer/filing/0001104659-24-064680#claim-6b89d27d43","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465924064680/0001104659-24-064680-index.htm"},{"fact_type":"material_agreement","fact_key":"3ec8b9667735587971f53857eabe5ad5abaf3a7f","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2024-05-13T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Collaboration and License Agreement","agreement_type":"collaboration","counterparty":"Sanofi Pasteur Inc.","effective_date":"2024-05-10","item_codes_triggered":["1.01"],"value_text":"$500 million"},"claim":"NOVAVAX INC entered into Collaboration and License Agreement with Sanofi Pasteur Inc. valued at $500 million (effective 2024-05-10).","evidence_excerpt":"On May 10, 2024, Novavax, Inc. (the “Company”) entered into a collaboration and license agreement (the “Collaboration and License Agreement”) with Sanofi Pasteur Inc. (“Sanofi”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-060444","anchor_url":"https://secwatch.observer/filing/0001104659-24-060444#claim-3ec8b9667735587971f53857eabe5ad5abaf3a7f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465924060444/0001104659-24-060444-index.htm"},{"fact_type":"earnings_release","fact_key":"9dcb71a47f6de8f1916217aa80490f57e7d35c02","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2024-05-10T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ended March 31, 2024","report_date":"2024-05-10","result_type":"reported_results","revenue_text":"$94 million"},"claim":"NOVAVAX INC reported the first quarter ended March 31, 2024 results: revenue $94 million.","evidence_excerpt":"half of 2024, with potential 2026 launch for both candidates · Reduced current liabilities by an additional $831 million during Q1 2024 · Achieved total revenue in Q1 2024 of $94 million · Novavax removes going concern notice · Company to host conference call today at 8:30\na.m. ET GAITHERSBURG, Md., May 10, 2024 –\nNovavax, Inc. (Nasdaq: NVAX), a global company","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-059659","anchor_url":"https://secwatch.observer/filing/0001104659-24-059659#claim-9dcb71a47f6de8f1916217aa80490f57e7d35c02","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465924059659/0001104659-24-059659-index.htm"},{"fact_type":"governance_change","fact_key":"ad2b6e4e6ed6c8ea747fa51eb3fb16e92ca3c8eb","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2024-04-26T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2024-04-22","item_codes_triggered":["5.03"],"summary_text":"Reduced quorum requirement for stockholder meetings from a majority to one-third (33 1/3%) of shares entitled to vote."},"claim":"NOVAVAX INC: Reduced quorum requirement for stockholder meetings from a majority to one-third (33 1/3%) of shares entitled to vote (effective 2024-04-22).","evidence_excerpt":"Effective April 22, 2024, the Board of Directors of Novavax, Inc. (the “Company”) adopted the Amended and Restated By-Laws of Novavax, Inc. (the “Amended and Restated By-Laws”), which reduced the quorum required for the transaction of business at stockholder meetings from the holders of a majority of the shares of the Company’s common stock, par value $0.01 per share (“Common Stock”), issued and outstanding and entitled to vote at a meeting to holders of one-third (33 1/3%) of the shares of Common Stock issued and outstanding and entitled to vote at such meeting (the “Quorum Requirement”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001000694-24-000013","anchor_url":"https://secwatch.observer/filing/0001000694-24-000013#claim-ad2b6e4e6ed6c8ea747fa51eb3fb16e92ca3c8eb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000100069424000013/0001000694-24-000013-index.htm"},{"fact_type":"material_agreement","fact_key":"a65e34734a9689683f9dbac67eeaceb8274376bc","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2024-03-26T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Confidential Settlement Agreement and Release","agreement_type":"settlement","counterparty":"FUJIFILM Diosynth Biotechnologies UK Limited, FUJIFILM Diosynth Biotechnologies Texas, LLC, and FUJIFILM Diosynth Biotechnologies USA, Inc.","effective_date":"2024-03-21","item_codes_triggered":["1.01"],"value_text":null},"claim":"NOVAVAX INC entered into Confidential Settlement Agreement and Release with FUJIFILM Diosynth Biotechnologies UK Limited, FUJIFILM Diosynth Biotechnologies Texas, LLC, and FUJIFILM Diosynth Biotechnologies USA, Inc. (effective 2024-03-21).","evidence_excerpt":"On March 21, 2024, Novavax, Inc. (the “Company”), FUJIFILM Diosynth Biotechnologies UK Limited (“FDBK”), FUJIFILM Diosynth Biotechnologies Texas, LLC (“FDBT”) and FUJIFILM Diosynth Biotechnologies USA, Inc. (“FDBU” and together with FDBK and FDBT, “Fujifilm”) entered into a Confidential Settlement Agreement and Release (the “Settlement Agreement”) to resolve disputes","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-039006","anchor_url":"https://secwatch.observer/filing/0001104659-24-039006#claim-a65e34734a9689683f9dbac67eeaceb8274376bc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465924039006/0001104659-24-039006-index.htm"},{"fact_type":"earnings_release","fact_key":"de8620a2e1e9eb45c8312ed21d13c77ae7634228","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2024-02-28T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and twelve months ended December 31, 2023","report_date":"2024-02-28","result_type":"reported_results","revenue_text":null},"claim":"NOVAVAX INC updated its the fourth quarter and twelve months ended December 31, 2023 guidance (reaffirmed).","evidence_excerpt":"On February 28, 2024, Novavax, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended December 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001000694-24-000009","anchor_url":"https://secwatch.observer/filing/0001000694-24-000009#claim-de8620a2e1e9eb45c8312ed21d13c77ae7634228","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000100069424000009/0001000694-24-000009-index.htm"},{"fact_type":"material_agreement","fact_key":"e2cf8a098f8adffb0f9eea9af893081d3efec3d7","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2024-02-22T23:59:59+00:00","payload":{"action":"termination","agreement_name":"Advance Purchase Agreement","agreement_type":"supply","counterparty":"Gavi Alliance","effective_date":"2024-02-16","item_codes_triggered":["1.02"],"value_text":null},"claim":"NOVAVAX INC terminated Advance Purchase Agreement with Gavi Alliance (effective 2024-02-16).","evidence_excerpt":"On February 16, 2024, Novavax, Inc. (the “Company”) and Gavi Alliance (“Gavi”) entered into a Termination and Settlement Agreement (the “Settlement Agreement”) terminating the Advance Purchase Agreement dated May 5, 2021 between the Company and Gavi (the “APA”), which related to the supply of the Company’s vaccine against SARS-COV-2 for the prevention of COVID-19, settling the arbitration proceedings initiated by Gavi against the Company (the “Arbitration”) relating to the APA and releasing both parties of all claims arising from, under or otherwise in connection with the APA.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-026225","anchor_url":"https://secwatch.observer/filing/0001104659-24-026225#claim-e2cf8a098f8adffb0f9eea9af893081d3efec3d7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465924026225/0001104659-24-026225-index.htm"},{"fact_type":"material_agreement","fact_key":"0bd3b60f41c67d7acf6b9d9900b01c0cda895708","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2024-02-22T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Settlement Agreement","agreement_type":"settlement","counterparty":"Gavi Alliance","effective_date":"2024-02-16","item_codes_triggered":["1.01"],"value_text":"total $400 million"},"claim":"NOVAVAX INC entered into Settlement Agreement with Gavi Alliance valued at total $400 million (effective 2024-02-16).","evidence_excerpt":"On February 16, 2024, Novavax, Inc. (the “Company”) and Gavi Alliance (“Gavi”) entered into a Termination and Settlement Agreement (the “Settlement Agreement”) terminating the Advance Purchase Agreement dated May 5, 2021 between the Company and Gavi (the “APA”), which related to the supply of the Company’s vaccine against SARS-COV-2 for the prevention of COVID-19, settling the arbitration proceedings initiated by Gavi against the Company (the “Arbitration”) relating to the APA and releasing both parties of all claims arising from, under or otherwise in connection with the APA.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-026225","anchor_url":"https://secwatch.observer/filing/0001104659-24-026225#claim-0bd3b60f41c67d7acf6b9d9900b01c0cda895708","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465924026225/0001104659-24-026225-index.htm"},{"fact_type":"earnings_release","fact_key":"fb488d8bb7253f8c6b57595fd4b85ba2e3e3e250","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2024-01-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the year ended December 31, 2023","report_date":"2024-01-08","result_type":"preliminary_results","revenue_text":null},"claim":"NOVAVAX INC updated its the year ended December 31, 2023 guidance (reaffirmed).","evidence_excerpt":"On January 8, 2024, Novavax, Inc. (the “Company”) provided an update for investors in which it reaffirmed its guidance for full year 2023 combined research and development and selling, general and administrative expenses, which is anticipated to be between $1.15 billion and $1.25 billion.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-002100","anchor_url":"https://secwatch.observer/filing/0001104659-24-002100#claim-fb488d8bb7253f8c6b57595fd4b85ba2e3e3e250","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465924002100/0001104659-24-002100-index.htm"},{"fact_type":"executive_change","fact_key":"25dd97dae2","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2023-11-17T23:59:59+00:00","payload":{"action":"retire","action_category":"departure","departure_tone":"retirement","effective_date":"2023-12-08","interim":false,"role":"Chief Legal Officer and Corporate Secretary","role_category":"general_counsel","successor_name":null,"successor_named":false},"claim":"John A. Herrmann III departed as Chief Legal Officer and Corporate Secretary at NOVAVAX INC.","evidence_excerpt":"John A. Herrmann III informed the Company of his intention to retire from his role as Chief Legal Officer and Corporate Secretary, effective December 8, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-119546","anchor_url":"https://secwatch.observer/filing/0001104659-23-119546#claim-25dd97dae2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465923119546/0001104659-23-119546-index.htm"},{"fact_type":"earnings_release","fact_key":"0af28d5ed8c43441f80c4ae3cea46677b0dcc833","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2023-11-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss of $131 million","period_text":"the third quarter ended September 30, 2023","report_date":"2023-11-09","result_type":"reported_results","revenue_text":"$187 million"},"claim":"NOVAVAX INC reported the third quarter ended September 30, 2023 results: revenue $187 million, net income Net loss of $131 million.","evidence_excerpt":"received recommendation from the World Health Organization; launch expected in 2024 2 Third Quarter 2023 Financial Results • Total revenue for the third quarter of 2023 was $187 million, compared to $735 million in the same period in 2022. Third quarter 2023 grant revenue of $165 million benefited from milestone achievements related to U.S. market preparedness","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001000694-23-000059","anchor_url":"https://secwatch.observer/filing/0001000694-23-000059#claim-0af28d5ed8c43441f80c4ae3cea46677b0dcc833","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000100069423000059/0001000694-23-000059-index.htm"},{"fact_type":"material_agreement","fact_key":"b0ff6aa5dfbb016f046dc5b080c83073dab5677e","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2023-08-08T23:59:59+00:00","payload":{"action":"termination","agreement_name":"Statement of Work No. 1 under the Collaboration and License Agreement","agreement_type":"license","counterparty":"SK bioscience Co., Ltd.","effective_date":"2023-08-08","item_codes_triggered":["1.02"],"value_text":"Termination of Statement of Work No. 1"},"claim":"NOVAVAX INC terminated Statement of Work No. 1 under the Collaboration and License Agreement with SK bioscience Co., Ltd. valued at Termination of Statement of Work No. 1 (effective 2023-08-08).","evidence_excerpt":"In connection with the parties’ entry into the Settlement Agreement, the Company and SK terminated Statement of Work No. 1 dated as of December 23, 2021 as amended to date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-088596","anchor_url":"https://secwatch.observer/filing/0001104659-23-088596#claim-b0ff6aa5dfbb016f046dc5b080c83073dab5677e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465923088596/0001104659-23-088596-index.htm"},{"fact_type":"material_agreement","fact_key":"c9f954374993795176e5805ee58d14fbc8886d7f","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2023-08-08T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Subscription Agreement","agreement_type":"equity_purchase","counterparty":"SK bioscience Co., Ltd.","effective_date":"2023-08-08","item_codes_triggered":["1.01"],"value_text":"$84.5 million for 6,500,000 shares of common stock at $13.00 per share"},"claim":"NOVAVAX INC entered into Securities Subscription Agreement with SK bioscience Co., Ltd. valued at $84.5 million for 6,500,000 shares of common stock at $13.00 per share (effective 2023-08-08).","evidence_excerpt":"On August 8, 2023, the Company also entered into a Securities Subscription Agreement (the “Subscription Agreement”) with SK, pursuant to which the Company agreed to sell and issue to SK, in a private placement (the “Private Placement”), 6,500,000 shares of the Company’s common stock, par value $0.01 per share (the “Shares”) at a price of $13.00 per share for aggregate gross proceeds to the Company of approximately $84.5 million.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-088596","anchor_url":"https://secwatch.observer/filing/0001104659-23-088596#claim-c9f954374993795176e5805ee58d14fbc8886d7f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465923088596/0001104659-23-088596-index.htm"},{"fact_type":"material_agreement","fact_key":"65526fcaeb6333f5990b9ba052d7bf4293770fa0","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2023-08-08T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Settlement Agreement and General Release","agreement_type":"settlement","counterparty":"SK bioscience Co., Ltd.","effective_date":"2023-08-08","item_codes_triggered":["1.01"],"value_text":"$149.75 million settlement payment"},"claim":"NOVAVAX INC entered into Settlement Agreement and General Release with SK bioscience Co., Ltd. valued at $149.75 million settlement payment (effective 2023-08-08).","evidence_excerpt":"On August 8, 2023, Novavax, Inc. (the “Company”) and SK bioscience Co., Ltd. (“SK”) entered into a Settlement Agreement and General Release (the “Settlement Agreement”) regarding mutual release by the parties of all claims arising from or in relation to certain statements of work canceled by the Company (as described below, the “Subject SOWs”) under the Development and Supply Agreement dated August 11, 2020 (“DSA”) and the Collaboration and License Agreement, dated February 12, 2021 as amended on December 23, 2021 and July 1, 2022 (“CLA”, collectively the “Business Agreements”), and other statements or work under the Business Agreements, in each case, in connection with the cessation of all drug substance and drug product manufacturing activity at SK for supply to the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-088596","anchor_url":"https://secwatch.observer/filing/0001104659-23-088596#claim-65526fcaeb6333f5990b9ba052d7bf4293770fa0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465923088596/0001104659-23-088596-index.htm"},{"fact_type":"earnings_release","fact_key":"6deceee62f8f807a6fcf663e161b253d05eb3fae","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2023-08-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$58 million","period_text":"Quarter Ended June 30, 2023","report_date":"2023-08-08","result_type":"reported_results","revenue_text":"$424 million"},"claim":"NOVAVAX INC reported Quarter Ended June 30, 2023 results: revenue $424 million, net income $58 million.","evidence_excerpt":"Novavax Reports Second Quarter 2023 Financial Results and Operational Highlights • Second quarter total revenue of $424 million and net income of $58 million","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001000694-23-000050","anchor_url":"https://secwatch.observer/filing/0001000694-23-000050#claim-6deceee62f8f807a6fcf663e161b253d05eb3fae","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000100069423000050/0001000694-23-000050-index.htm"},{"fact_type":"shareholder_vote","fact_key":"fffb2a5355520b5ecef96010a3321c1cc975729b","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2023-07-11T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-07-11","outcome":"passed","proposal_text":"Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"384,804","votes_against":"2,005,826","votes_for":"41,350,254","votes_withheld":null}]},"claim":"NOVAVAX INC shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-07-11 meeting.","evidence_excerpt":"Proposal 6 : Stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023: For Against Abstaining Broker Non-Votes 41,350,254 2,005,826 384,804 —","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-080024","anchor_url":"https://secwatch.observer/filing/0001104659-23-080024#claim-fffb2a5355520b5ecef96010a3321c1cc975729b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465923080024/0001104659-23-080024-index.htm"},{"fact_type":"shareholder_vote","fact_key":"7932bc38235814be5590a7f923f723a9a8adb4c2","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2023-07-11T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-07-11","outcome":"passed","proposal_text":"Amendment and restatement of the Novavax Inc. Amended and Restated 2015 Stock Incentive Plan to increase the number of shares available for issuance by 6,170,000","proposal_type":"equity_plan","results":[{"broker_non_votes":"24,476,819","subject":null,"votes_abstain":"308,114","votes_against":"3,824,183","votes_for":"15,131,768","votes_withheld":null}]},"claim":"NOVAVAX INC shareholders approved Amendment and restatement of the Novavax Inc. Amended and Restated 2015 Stock Incentive Plan to increase the number of shares available for issuance by 6,170,000 at the 2023-07-11 meeting.","evidence_excerpt":"Proposal 5 : Stockholders approved the amendment and restatement of the Novavax Inc. Amended and Restated 2015 Stock Incentive Plan to increase the number of shares of Common Stock available for issuance thereunder by 6,170,000 shares: For Against Abstaining Broker Non-Votes 15,131,768 3,824,183 308,114 24,476,819","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-080024","anchor_url":"https://secwatch.observer/filing/0001104659-23-080024#claim-7932bc38235814be5590a7f923f723a9a8adb4c2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465923080024/0001104659-23-080024-index.htm"},{"fact_type":"shareholder_vote","fact_key":"a6c1ab151a3b2782cd69dd1572855592415941dd","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2023-07-11T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-07-11","outcome":"failed","proposal_text":"Amendment to the Second Amended and Restated Certificate of Incorporation to reflect Delaware law provisions allowing officer exculpation","proposal_type":"charter_amendment","results":[{"broker_non_votes":"24,476,819","subject":null,"votes_abstain":"458,331","votes_against":"2,058,948","votes_for":"16,746,786","votes_withheld":null}]},"claim":"NOVAVAX INC shareholders rejected Amendment to the Second Amended and Restated Certificate of Incorporation to reflect Delaware law provisions allowing officer exculpation at the 2023-07-11 meeting.","evidence_excerpt":"Proposal 4 : Stockholders did not approve the amendment to the Second Amended and Restated Certificate of Incorporation of Novavax, Inc. to reflect Delaware law provisions allowing officer exculpation: For Against Abstaining Broker Non-Votes 16,746,786 2,058,948 458,331 24,476,819","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-080024","anchor_url":"https://secwatch.observer/filing/0001104659-23-080024#claim-a6c1ab151a3b2782cd69dd1572855592415941dd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465923080024/0001104659-23-080024-index.htm"},{"fact_type":"shareholder_vote","fact_key":"0dfaec73720aeef5a87c6161c7082dcb39c1b48a","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2023-07-11T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-07-11","outcome":"passed","proposal_text":"Advisory vote on the frequency of future named executive officer compensation votes","proposal_type":"say_on_pay_frequency","results":[{"broker_non_votes":null,"subject":"One Year","votes_abstain":null,"votes_against":null,"votes_for":"17,803,121","votes_withheld":null},{"broker_non_votes":null,"subject":"Two Years","votes_abstain":null,"votes_against":null,"votes_for":"342,423","votes_withheld":null},{"broker_non_votes":null,"subject":"Three Years","votes_abstain":null,"votes_against":null,"votes_for":"846,988","votes_withheld":null},{"broker_non_votes":null,"subject":"Abstaining","votes_abstain":"271,533","votes_against":null,"votes_for":null,"votes_withheld":null},{"broker_non_votes":"24,476,819","subject":"Broker Non-Votes","votes_abstain":null,"votes_against":null,"votes_for":null,"votes_withheld":null}]},"claim":"NOVAVAX INC shareholders approved Advisory vote on the frequency of future named executive officer compensation votes at the 2023-07-11 meeting.","evidence_excerpt":"Proposal 3 : Stockholders approved, on an advisory basis, the frequency of future named executive officer compensation votes: One Year Two Years Three Years Abstaining Broker Non-Votes 17,803,121 342,423 846,988 271,533 24,476,819","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-080024","anchor_url":"https://secwatch.observer/filing/0001104659-23-080024#claim-0dfaec73720aeef5a87c6161c7082dcb39c1b48a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465923080024/0001104659-23-080024-index.htm"},{"fact_type":"shareholder_vote","fact_key":"b91137b724cd0b7b539ee522baaa3204b0771cd1","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2023-07-11T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-07-11","outcome":"passed","proposal_text":"Advisory vote on the compensation paid to the Company’s named executive officers in 2022","proposal_type":"say_on_pay","results":[{"broker_non_votes":"24,476,819","subject":null,"votes_abstain":"538,435","votes_against":"3,030,052","votes_for":"15,695,578","votes_withheld":null}]},"claim":"NOVAVAX INC shareholders approved Advisory vote on the compensation paid to the Company’s named executive officers in 2022 at the 2023-07-11 meeting.","evidence_excerpt":"Proposal 2 : Stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers in 2022: For Against Abstaining Broker Non-Votes 15,695,578 3,030,052 538,435 24,476,819","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-080024","anchor_url":"https://secwatch.observer/filing/0001104659-23-080024#claim-b91137b724cd0b7b539ee522baaa3204b0771cd1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465923080024/0001104659-23-080024-index.htm"},{"fact_type":"shareholder_vote","fact_key":"a47afd8a761356a8b41d476389d96d27ed9d9ad9","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2023-07-11T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-07-11","outcome":"passed","proposal_text":"Election of Class I nominees for director","proposal_type":"director_election","results":[{"broker_non_votes":"24,476,819","subject":"John C. Jacobs","votes_abstain":"285,358","votes_against":"881,806","votes_for":"18,096,901","votes_withheld":null},{"broker_non_votes":"24,476,819","subject":"Gregg H. Alton, J.D.","votes_abstain":"446,333","votes_against":"7,498,303","votes_for":"11,319,429","votes_withheld":null},{"broker_non_votes":"24,476,819","subject":"Richard J. Rodgers","votes_abstain":"462,842","votes_against":"5,662,283","votes_for":"13,138,940","votes_withheld":null}]},"claim":"NOVAVAX INC shareholders approved Election of Class I nominees for director at the 2023-07-11 meeting.","evidence_excerpt":"Proposal 1 : Stockholders elected the following Class I nominees for director, each to serve a three-year term expiring at the 2026 Annual Meeting of Stockholders: Name For Against Abstain Broker Non-Votes John C. Jacobs 18,096,901 881,806 285,358 24,476,819 Gregg H. Alton, J.D. 11,319,429 7,498,303 446,333 24,476,819 Richard J. Rodgers 13,138,940 5,662,283 462,842 24,476,819","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-080024","anchor_url":"https://secwatch.observer/filing/0001104659-23-080024#claim-a47afd8a761356a8b41d476389d96d27ed9d9ad9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465923080024/0001104659-23-080024-index.htm"},{"fact_type":"material_agreement","fact_key":"8dae710b50c2511ada3386a8067f287325901d1e","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2023-07-07T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amendment","agreement_type":"supply","counterparty":"His Majesty the King in right of Canada, as represented by the Minister of Public Works and Government Services","effective_date":"2023-06-30","item_codes_triggered":["1.01"],"value_text":"$349.6 million"},"claim":"NOVAVAX INC amended Amendment with His Majesty the King in right of Canada, as represented by the Minister of Public Works and Government Services valued at $349.6 million (effective 2023-06-30).","evidence_excerpt":"On June 30, 2023, Novavax, Inc. (the “ Company ”) entered into an amendment (the “ Amendment ”) to its advanced purchase agreement (the “ Advanced Purchase Agreement ”) with His Majesty the King in right of Canada, as represented by the Minister of Public Works and Government Services, as successor in interest to Her Majesty the Queen in right of Canada, as represented by the Minister of Public Works and Government Services (the “ Customer ”), dated January 19, 2021.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-079096","anchor_url":"https://secwatch.observer/filing/0001104659-23-079096#claim-8dae710b50c2511ada3386a8067f287325901d1e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465923079096/0001104659-23-079096-index.htm"},{"fact_type":"earnings_release","fact_key":"b3d05a4394695693872b185ba59b7b630a14fad7","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2023-05-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"full year 2023","report_date":"2023-05-09","result_type":"guidance_update","revenue_text":"$1.4 and $1.6 billion"},"claim":"NOVAVAX INC reported full year 2023 results: revenue $1.4 and $1.6 billion. Guidance initiated.","evidence_excerpt":"Provided full year 2023 total revenue guidance of between $1.4 and $1.6 billion","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001000694-23-000039","anchor_url":"https://secwatch.observer/filing/0001000694-23-000039#claim-b3d05a4394695693872b185ba59b7b630a14fad7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000100069423000039/0001000694-23-000039-index.htm"},{"fact_type":"earnings_release","fact_key":"b33f3a287ccb7cc3b45f04350174c5d18a295077","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2023-05-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$294 million","period_text":"first quarter ended March 31, 2023","report_date":"2023-05-09","result_type":"reported_results","revenue_text":"$81 million"},"claim":"NOVAVAX INC reported first quarter ended March 31, 2023 results: revenue $81 million, net income $294 million.","evidence_excerpt":"First Quarter 2023 Financial Results • Total revenue: Due to an emerging seasonal demand pattern for COVID vaccines, total revenue for the first quarter of 2023 was $81 million compared to $704 million in the same period in 2022. First quarter 2023 product sales include a $65 million revenue reversal associated with doses delivered in 2022 that are scheduled for future replacement. • Cost of sales for the first quarter of 2023 were $34 million, compared to $15 million in the same period in 2022. This includes $20 million related to excess, obsolete, or expired inventory and losses on firm purchase commitments. • Research and development expenses (R&D) for the first quarter of 2023 were $247 million, compared to $383 million in the same period in 2022. The decrease was primarily due to a reduction in clinical and manufacturing spend. • Selling, general and administrative expenses (SG&A) for the first quarter of 2023 were $113 million, compared to $96 million for the same period in 2022.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001000694-23-000039","anchor_url":"https://secwatch.observer/filing/0001000694-23-000039#claim-b33f3a287ccb7cc3b45f04350174c5d18a295077","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000100069423000039/0001000694-23-000039-index.htm"},{"fact_type":"restructuring_charge","fact_key":"0fb4bc97b775c8bfdad8e1a743e72e96634c5ff9","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2023-05-09T23:59:59+00:00","payload":{"affected_area":null,"charge_text":"approximately $10 million to $15 million","effective_date":"2023-05-08","event_type":"restructuring","headcount_text":"approximately 25% reduction of its global workforce","item_codes_triggered":["2.05"]},"claim":"NOVAVAX INC announced a restructuring with charges of approximately $10 million to $15 million (approximately 25% reduction of its global workforce).","evidence_excerpt":"On May 8, 2023, the Board of Directors of the Company approved an approximately 25% reduction of its global workforce, comprised of an approximately 20% reduction in the Company’s full-time employees and the remainder comprised of contractors and consultants. The Company expects the full annual impact of the cost savings to be realized in 2024 and approximately half of the annual impact, excluding one-time charges, to be realized in 2023 due to timing of implementing the measures, and the applicable laws, regulations, and other factors in the jurisdictions in which it operates. The Company is expected to record a charge of approximately $10 million to $15 million related one-time employee severance and benefit costs, the majority of which is expected to be incurred in the second quarter of 2023 and it is evaluating the anticipated cost related to the consolidation of facilities and infrastructure.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001000694-23-000039","anchor_url":"https://secwatch.observer/filing/0001000694-23-000039#claim-0fb4bc97b775c8bfdad8e1a743e72e96634c5ff9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000100069423000039/0001000694-23-000039-index.htm"},{"fact_type":"governance_change","fact_key":"0ed6bbdf89d2c77e93b45d5411b7d19b1edf805d","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2023-04-04T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2023-03-30","item_codes_triggered":["5.03"],"summary_text":"Amended and restated bylaws to reflect changes in DGCL regarding adjourned meetings, stockholder list, and stock certificate signing"},"claim":"NOVAVAX INC: Amended and restated bylaws to reflect changes in DGCL regarding adjourned meetings, stockholder list, and stock certificate signing (effective 2023-03-30).","evidence_excerpt":"Effective March 30, 2023, the Board of Directors (the “Board”) of Novavax, Inc. (the “Company”) adopted the Amended and Restated By-Laws of Novavax, Inc. (the “Amended and Restated By-Laws”) to reflect amendments to the Delaware General Corporation Law (the “DGCL”) regarding notice of adjourned stockholder meetings and eliminating the requirement of having a stockholder list available at a stockholder meeting, which amendments became effective in August 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001000694-23-000011","anchor_url":"https://secwatch.observer/filing/0001000694-23-000011#claim-0ed6bbdf89d2c77e93b45d5411b7d19b1edf805d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000100069423000011/0001000694-23-000011-index.htm"},{"fact_type":"executive_change","fact_key":"ad95faa044","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2023-03-22T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":"2023-03-31","interim":false,"role":"President, Research and Development","role_category":"president","successor_name":null,"successor_named":false},"claim":"Gregory M. Glenn retired as President, Research and Development at NOVAVAX INC.","evidence_excerpt":"Dr. Gregory M. Glenn, M.D. notified Novavax Inc. (the “Company”) of his decision to retire as President, Research and Development, effective as of March 31, 2023.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001000694-23-000008","anchor_url":"https://secwatch.observer/filing/0001000694-23-000008#claim-ad95faa044","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000100069423000008/0001000694-23-000008-index.htm"},{"fact_type":"executive_change","fact_key":"8398a710f5","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2023-03-02T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":"2023-03-31","interim":false,"role":"President, Research and Development","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Dr. Gregory M. Glenn retired as President, Research and Development at NOVAVAX INC.","evidence_excerpt":"On February 28, 2023, Dr. Gregory M. Glenn, M.D. notified Novavax Inc. (the “Company”) of his decision to retire as President, Research and Development, effective as of March 31, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-028031","anchor_url":"https://secwatch.observer/filing/0001104659-23-028031#claim-8398a710f5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465923028031/0001104659-23-028031-index.htm"},{"fact_type":"earnings_release","fact_key":"0af6437e0081b2f0eb68248324747826b55423ca","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2023-02-28T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"full year 2022","report_date":"2023-02-28","result_type":"reported_results","revenue_text":"$1.9 billion"},"claim":"NOVAVAX INC reported full year 2022 results: revenue $1.9 billion.","evidence_excerpt":"Total revenue for the full year 2022 was $1.9 billion","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-026709","anchor_url":"https://secwatch.observer/filing/0001104659-23-026709#claim-0af6437e0081b2f0eb68248324747826b55423ca","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465923026709/0001104659-23-026709-index.htm"},{"fact_type":"earnings_release","fact_key":"7fb1c0b266c27c8e261c9b7d2623bf329b114578","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2023-02-28T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"fourth quarter 2022","report_date":"2023-02-28","result_type":"reported_results","revenue_text":"$357 million"},"claim":"NOVAVAX INC reported fourth quarter 2022 results: revenue $357 million.","evidence_excerpt":"Total revenue for the fourth quarter 2022 was $357 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-026709","anchor_url":"https://secwatch.observer/filing/0001104659-23-026709#claim-7fb1c0b266c27c8e261c9b7d2623bf329b114578","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465923026709/0001104659-23-026709-index.htm"},{"fact_type":"executive_change","fact_key":"f001864444","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2023-01-09T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-01-23","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"John C. Jacobs was appointed as President and Chief Executive Officer at NOVAVAX INC.","evidence_excerpt":"the Board of Directors (the “Board”) of Novavax, Inc. (the “Company”) approved the appointment of John C. Jacobs, age 56, as President and Chief Executive Officer and a member of the Board, effective as of January 23, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-002102","anchor_url":"https://secwatch.observer/filing/0001104659-23-002102#claim-f001864444","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465923002102/0001104659-23-002102-index.htm"},{"fact_type":"executive_change","fact_key":"dc89b882e8","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2023-01-09T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":"2023-01-23","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":"John C. Jacobs","successor_named":true},"claim":"Stanley C. Erck retired as President and Chief Executive Officer at NOVAVAX INC.","evidence_excerpt":"Mr. Jacobs will succeed Stanley C. Erck, who provided the Board with notice on January 5, 2023 of his decision to retire as President and Chief Executive Officer and as a member of the Board, in each case effective as of January 23, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-002102","anchor_url":"https://secwatch.observer/filing/0001104659-23-002102#claim-dc89b882e8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465923002102/0001104659-23-002102-index.htm"},{"fact_type":"debt_financing","fact_key":"964a467f31900ce6b354afc1f52eca49041f647e","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2022-12-28T23:59:59+00:00","payload":{"counterparty":"J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC","effective_date":"2022-12-23","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"5.00%","item_codes_triggered":["2.03"],"maturity_text":"due 2027","principal_text":"$25.25 million"},"claim":"NOVAVAX INC incurred convertible notes of $25.25 million with J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC at 5.00% maturing due 2027.","evidence_excerpt":"On December 23, 2022, Novavax, Inc. (the “Company”) completed the issuance and sale of $25.25 million aggregate principal amount of the Company’s 5.00% Convertible Senior Notes due 2027 (the “Additional Notes”) to J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC, as representatives (the “Representatives”) of the several initial purchasers","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-22-130566","anchor_url":"https://secwatch.observer/filing/0001104659-22-130566#claim-964a467f31900ce6b354afc1f52eca49041f647e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465922130566/0001104659-22-130566-index.htm"},{"fact_type":"material_agreement","fact_key":"dc026f66f0483b35cb1efa5d37c68a2eabb93bfc","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2022-12-28T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"notes_offering","counterparty":"J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC","effective_date":"2022-12-15","item_codes_triggered":["1.01"],"value_text":"$25.25 million"},"claim":"NOVAVAX INC entered into Purchase Agreement with J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC valued at $25.25 million (effective 2022-12-15).","evidence_excerpt":"On December 23, 2022, Novavax, Inc. (the “Company”) completed the issuance and sale of $25.25 million aggregate principal amount of the Company’s 5.00% Convertible Senior Notes due 2027 (the “Additional Notes”) to J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC, as representatives (the “Representatives”) of the several initial purchasers (the “Initial Purchasers”), pursuant to their election to purchase Additional Notes, which was exercised in full, pursuant to the purchase agreement, dated as of December 15, 2022, by and among the Company and the Initial Purchasers (the “Purchase Agreement”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-22-130566","anchor_url":"https://secwatch.observer/filing/0001104659-22-130566#claim-dc026f66f0483b35cb1efa5d37c68a2eabb93bfc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465922130566/0001104659-22-130566-index.htm"},{"fact_type":"debt_financing","fact_key":"6e85fddb98c773d9fee6d7b23236463a8c849be5","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2022-12-21T23:59:59+00:00","payload":{"counterparty":"The Bank of New York Mellon Trust Company, N.A.","effective_date":"2022-12-20","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"5.00% per year","item_codes_triggered":["2.03"],"maturity_text":"December 15, 2027","principal_text":"$150 million aggregate principal amount"},"claim":"NOVAVAX INC incurred convertible notes of $150 million aggregate principal amount with The Bank of New York Mellon Trust Company, N.A. at 5.00% per year maturing December 15, 2027.","evidence_excerpt":"On December 20, 2022, Novavax, Inc. (the “Company”) completed its previously announced offering of $150 million aggregate principal amount of 5.00% Convertible Senior Notes due 2027 (the “Notes”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-22-128864","anchor_url":"https://secwatch.observer/filing/0001104659-22-128864#claim-6e85fddb98c773d9fee6d7b23236463a8c849be5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465922128864/0001104659-22-128864-index.htm"},{"fact_type":"material_agreement","fact_key":"8f9c1c611dd944ac64724b1cde29422da7c56be3","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2022-12-21T23:59:59+00:00","payload":{"action":"entry","agreement_name":"5.00% Convertible Senior Notes due 2027 Indenture","agreement_type":"notes_offering","counterparty":"The Bank of New York Mellon Trust Company, N.A.","effective_date":"2022-12-20","item_codes_triggered":["1.01"],"value_text":"$150 million aggregate principal amount of 5.00% Convertible Senior Notes due 2027"},"claim":"NOVAVAX INC entered into 5.00% Convertible Senior Notes due 2027 Indenture with The Bank of New York Mellon Trust Company, N.A. valued at $150 million aggregate principal amount of 5.00% Convertible Senior Notes due 2027 (effective 2022-12-20).","evidence_excerpt":"On December 20, 2022, Novavax, Inc. (the “Company”) completed its previously announced offering of $150 million aggregate principal amount of 5.00% Convertible Senior Notes due 2027 (the “Notes”). The Notes were offered and sold only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with the offering of the Notes, the Company granted to the initial purchasers a 30-day option to purchase up to an additional $25.25 million aggregate principal amount of the Notes. The Notes were issued pursuant to an indenture, dated December 20, 2022 (the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-22-128864","anchor_url":"https://secwatch.observer/filing/0001104659-22-128864#claim-8f9c1c611dd944ac64724b1cde29422da7c56be3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465922128864/0001104659-22-128864-index.htm"},{"fact_type":"material_agreement","fact_key":"42d4631448a5b3dd0b0f334d032ddb41876af405","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2022-12-19T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC, as representatives of the several underwriters","effective_date":"2022-12-15","item_codes_triggered":["1.01"],"value_text":"6,500,000 shares of common stock at a public offering price of $10.00 per share"},"claim":"NOVAVAX INC entered into Underwriting Agreement with J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC, as representatives of the several underwriters valued at 6,500,000 shares of common stock at a public offering price of $10.00 per share (effective 2022-12-15).","evidence_excerpt":"On December 15, 2022, Novavax, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC, as representatives of the several underwriters named in Schedule I thereto (collectively, the “Underwriters”), relating to the public offering by the Company of 6,500,000 shares of its common stock, par value $0.01 per share (“Common Stock”), at a public offering price of $10.00 per share, less underwriting discounts and commissions","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-22-128263","anchor_url":"https://secwatch.observer/filing/0001104659-22-128263#claim-42d4631448a5b3dd0b0f334d032ddb41876af405","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465922128263/0001104659-22-128263-index.htm"},{"fact_type":"material_agreement","fact_key":"58780a13c6b9e28925ed385c1bd6387dd6a71346","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2022-11-21T23:59:59+00:00","payload":{"action":"termination","agreement_name":"Advance Purchase Agreement","agreement_type":"supply","counterparty":"Gavi Alliance","effective_date":"2022-11-18","item_codes_triggered":["1.02"],"value_text":null},"claim":"NOVAVAX INC terminated Advance Purchase Agreement with Gavi Alliance (effective 2022-11-18).","evidence_excerpt":"On November 18, 2022, Novavax, Inc. (the “Company”) delivered written notice to the Gavi Alliance (“Gavi”) to terminate, effective immediately, the Advance Purchase Agreement, dated May 5, 2021, by and between the Company and Gavi (the “APA”) on the basis of Gavi’s material breach of the APA due to Gavi’s failure to procure the purchase of 350 million doses of NVX-CoV2373 from the Company as required by Section 2.1 of the APA and Gavi’s inability to cure such failure.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-22-120848","anchor_url":"https://secwatch.observer/filing/0001104659-22-120848#claim-58780a13c6b9e28925ed385c1bd6387dd6a71346","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465922120848/0001104659-22-120848-index.htm"},{"fact_type":"earnings_release","fact_key":"63de8330140cf17fc91f187447fca2909a61c11a","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2022-11-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"unknown","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the third quarter ended September 30, 2022","report_date":"2022-11-08","result_type":"reported_results","revenue_text":"$735 million"},"claim":"NOVAVAX INC reported the third quarter ended September 30, 2022 results: revenue $735 million.","evidence_excerpt":"· Achieved total revenue for the third quarter of $735 million · Delivered over 94 million doses of NVX-CoV2373 globally to date · Authorized as a booster for adults in the U.S., E.U., and additional markets · Authorized as a primary series for adolescents aged 12 – 17 years in U.S., EU, Japan, and additional markets · Announced data about our prototype’s broad immune response against circulating variants when used as a booster · Initiated NVX-CoV2373 Phase 2b/3 study in children 6 months through 11 years of age · Refining full year 2022 total revenue guidance to approximately $2.0 billion · Company to host conference call today at 4:30 p.m. ET GAITHERSBURG, Md., November 8, 2022 – Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the third quarter ended September 30, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-22-115937","anchor_url":"https://secwatch.observer/filing/0001104659-22-115937#claim-63de8330140cf17fc91f187447fca2909a61c11a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465922115937/0001104659-22-115937-index.htm"},{"fact_type":"executive_change","fact_key":"294f79092f","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2022-11-01T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-10-29","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Richard J. Rodgers was appointed as Director at NOVAVAX INC.","evidence_excerpt":"On October 29, 2022, the Board of Directors (the “Board”) of Novavax, Inc. (the “Company”) voted to increase the size of the Board from seven members to eight members and to appoint Richard J. Rodgers to the Board to fill the resulting vacancy, effective as of October 29, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-22-113551","anchor_url":"https://secwatch.observer/filing/0001104659-22-113551#claim-294f79092f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465922113551/0001104659-22-113551-index.htm"},{"fact_type":"executive_change","fact_key":"d49a636d9b","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2022-03-07T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"not_disclosed","effective_date":"2022-03-05","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Rajiv I. Modi resigned as Director at NOVAVAX INC.","evidence_excerpt":"Rajiv I. Modi, Ph.D. notified the Board of Directors (the \"Board\") of Novavax, Inc. of his resignation from the Board, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-22-031110","anchor_url":"https://secwatch.observer/filing/0001104659-22-031110#claim-d49a636d9b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465922031110/0001104659-22-031110-index.htm"},{"fact_type":"executive_change","fact_key":"76c7e533e0","cik":1000694,"ticker":"NVAX","company_name":"NOVAVAX INC","filed_at":"2021-08-18T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-08-16","interim":false,"role":"Executive Vice President, Chief Financial Officer and Treasurer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"James P. Kelly was appointed as Executive Vice President, Chief Financial Officer and Treasurer at NOVAVAX INC.","evidence_excerpt":"announced the appointment of James P. Kelly, age 55, as Executive Vice President, Chief Financial Officer and Treasurer of the Company, effective August 16, 2021.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-21-107375","anchor_url":"https://secwatch.observer/filing/0001104659-21-107375#claim-76c7e533e0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465921107375/0001104659-21-107375-index.htm"}]}